Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05029882
Title	Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	AbbVie
Indications	colorectal cancer lung non-small cell carcinoma renal cell carcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma Advanced Solid Tumor
Therapies	ABBV-400 + Bevacizumab ABBV-400 Bevacizumab + Trifluridine-tipiracil hydrochloride
Age Groups:	adult \| senior
Covered Countries	USA \| FRA \| ESP \| AUS